Safety issues related to emerging therapies for rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  Keystone, Edward C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Abatacept (CTLA4Ig); Biologics therapy; Rheumatoid arthritis; Rituximab (anti CD20)

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; CD20 ANTIBODY; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; CD28 ANTIGEN; CORTICOSTEROID;

ABSCESS; ANEMIA; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BRONCHITIS; BRONCHOPNEUMONIA; CLINICAL TRIAL; CORNEA DISEASE; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FLUSHING; GASTROENTERITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION; INFUSION REACTION; KIDNEY DYSFUNCTION; LARYNGITIS; NONHUMAN; PERICARDITIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; SEPTICEMIA; SIDE EFFECT; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; DIZZINESS; FEVER; HEADACHE; HUMORAL IMMUNE DEFICIENCY; MONOTHERAPY; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; T LYMPHOCYTE ACTIVATION; TRACHEOBRONCHITIS; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RISK ASSESSMENT; SAFETY;

EID: 4944226966     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. PANAYI GS, CORRIGALL VM, PITZALIS C: Pathogenesis of rheumatoid arthritis. Role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27: 317.
2. FINCK BK, KINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4-Ig. Science 1994; 265: 1225.
3. KNOERZER DB, KARR RW, SCHWARTZ BD et al.: Collagen-induced arthritis in the BB rat: Prevention of disease by treatment with CTLA4-Ig. J Clin Invest 1995; 96: 987.
4. ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4-Ig mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243.
5. KREMER J, WESTHOVENS R, LEON M et al.: A phase IIb multi-center, randomized double-blind placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4-Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate. N Engl Med J 2004; 349: 1907-14
6. KEYSTONE EC, SIBILIA J, STEINFELD, S, NUAMAH I, ARANDA R, BECKER J: Efficiency of Abatacept (CTLA4 Ig; BMS 188667) in combination with methotrexate in the treatment of early and established rheumatoid arthritis. Anti Rheum Dis 2004; 63: Abstract OP0104.
7. WEINBLATT M, SCHIFF M, GOLDMAN M et al.: A pilot, multi-center, randomized, double-blind, placebo controlled trial of a co-stimulatory blocker CTLA4-Ig) (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritis Rheum 2002; 46 (Suppl.): S204 (Abstract 464).
8. TAKEMURA S, KLIMIUK PA, BRAUN A et al.: T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167: 4710.
9. EDWARDS JCW, CAMBRIDGE G: Sustained improvement in RA following a protocol designed to deplete B lymphocytes. Rheumatology 2001; 40: 205-11.
10. LEANDRO MD, EDWARDS JCW, CAMBRIDGE G: Clinical outcome in 22 patients with RA treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-8.
11. EDWARDS JCW, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy and safety of Rituximab, a B cell targeted chimeric monoclonal antibody: a placebo RCT in patients with RA. Arthritis Rheum 2002; 46 (Suppl. 9): S197.
12. EMERY P, SZCZEPANSKI L, SZECHINSKI J et al.: Sustained efficacy at 48 weeks after single treatment course of Rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: S439 (abstract 1095).
13. STAHL ND, SZCZEPANSKI L, SZECHINSKI J et al.: Rituximab in RA: efficiency and safety from a randomized controlled trial. Ann Rheum Dis 2003; 62 (Suppl. 1): OP0004 (abstr.).
14. SZECHINSKI, J, SZCZEPANSKI L, FILIPOWICZ-SOSNOWSKA A et al.: Treatment of RA with Rituximab leads to selective peripheral B-cell depletion with minimal effect on immunoglobulins. Ann Rheum Dis 2003; 62: Thu 0205 (abst.).
15. CAMBRIDGE G, LEANDRO MJ, EDWARDS JCW et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-54.
16. SZCZEPANSKI L, SZECHINSKI, J, FILIPOWICZ-SOSNOWSKA A et al.: Infusions of Rituximab in patients with rheumatoid arthritis are well tolerated. Ann Rheum Dis 2003, 62: thu 0206 (abstr.).
17. SZCZEPANSKI, L, SZECHINSKI J, FILIPOWICZ-SOSNOWSKA A et al.: Safety data from 48 week follow-up of a randomized controlled trial of Rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48 (Suppl.): S121 (Abstract 204).
18. TUSCANO JM: Successful treatment of infliximab-refractory rheumatoid arthritis with Rituximab. Presented at the American College of Rheumatology Annual Meeting 2002. Late breaking abstract.